Get started
Author

Stefano Soddu

Observed name: S. Soddu
Observed institution: Fondazione Gimema Onlus
ORCID: 0000-0002-1942-1230
Observed ORCID: 0000-0002-1942-1230
OpenAlex ID: A5103011236
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL
2023 · Robin Foà, Renato Bassan, et al. · Journal of Clinical Oncology · 189
PDF
Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
2018 · Anna Lucia Fedullo, Monica Messina, et al. · Haematologica · 88
PDF
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome
2018 · Maria Ilaria Del Principe, Francesco Buccisano, et al. · Seminars in Hematology · 66
Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2024 · Sabina Chiaretti, Matteo Leoncin, et al. · Blood · 37
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
2022 · Carmelo Gurnari, Alfonso Piciocchi, et al. · Blood Cancer Journal · 21
PDF
First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients
2025 · Sabina Chiaretti, Mariangela Di Trani, et al. · Blood · 19
PDF
Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial
2023 · Sabina Chiaretti, Matteo Leoncin, et al. · Blood · 17
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey
2020 · Massimo Breccia, Alfonso Piciocchi, et al. · Leukemia · 16
PDF
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey
2020 · Francesca Palandri, Alfonso Piciocchi, et al. · Leukemia · 16
PDF
Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation
2022 · Giovanni Marconi, Alfonso Piciocchi, et al. · Blood · 14
Prognostic impact of KMT2A‐AFF1 ‐positivity in 926 BCR‐ABL1 ‐negative B‐lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996
2021 · Alfonso Piciocchi, Monica Messina, et al. · American Journal of Hematology · 12
PDF
Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients
2024 · Alfonso Piciocchi, Marta Cipriani, et al. · eJHaem · 10
PDF
Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial
2025 · Alessandro Vannucchi, Francesco Mannelli, et al. · Blood · 8
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab
2020 · Nadia Peragine, Maria Stefania De Propris, et al. · Haematologica · 8
PDF
An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920)
2021 · Lydia Scarfo, Elisa Albi, et al. · Blood · 7
Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial
2023 · Adriano Venditti, Alfonso Piciocchi, et al. · Blood · 6
Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
2022 · M. Breccia, A. Piciocchi, et al. · Leukemia · 6
PDF
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study
2018 · Francesca Romana Mauro, Stefano Soddu, et al. · Blood · 5
Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
2021 · Francesco Buccisano, Raffaele Palmieri, et al. · Cancers · 4
PDF
Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine
2025 · Paola Guglielmelli, Francesca Crupi, et al. · Blood · 3
PDF
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
2023 · Massimo Breccia, Alfonso Piciocchi, et al. · Journal of Clinical Medicine · 3
Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL
2026 · Sabina Chiaretti, Alfonso Piciocchi, et al. · New England Journal of Medicine · 2
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice
2024 · Monica Messina, Alfonso Piciocchi, et al. · eJHaem · 2
PDF
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)
2020 · Francesca R. Mauro, Stefano Molica, et al. · Haematologica · 2
PDF
Prognostic Impact of t(4;11)(q21;q23)/KMT2A-AFF1-Positivity in 926 BCR-ABL1-Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996
2019 · Alfonso Piciocchi, Monica Messina, et al. · Blood · 2
Works count: 42
Citation count: 570
H-index: 11
I10-index: 12
Year
Topic
Type